The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

Acta Haematologica
D MacdonaldNicholas C P Cross

Abstract

Several recurrent translocations that involve chromosome band 8p11 have been described in myeloid malignancies. These translocations target two distinct genes: (1) FGFR1, a receptor tyrosine kinase for fibroblast growth factors, and (2) MOZ, a putative histone acetyltransferase whose precise function remains to be defined. Disruption of FGFR1 is associated with a disease entity known as the 8p11 myeloproliferative syndrome (EMS)/stem cell leukemia-lymphoma syndrome, a chronic myeloproliferative disorder that frequently presents with eosinophilia and associated T-cell lymphoblastic lymphoma. The disease is aggressive and rapidly transforms to acute leukaemia, usually of myeloid phenotype. Currently, only allogeneic stem cell transplantation appears to be effective in eradicating or suppressing the malignant clone. To date, four gene fusions associated with distinct translocations have been described in EMS: the t(8;13)(p11;q12), t(8;9)(p11;q33), t(6;8)(q27;p11) and t(8;22)(p11q22) fuse ZNF198, CEP110, FOP and BCR, respectively, to FGFR1. The resulting fusion proteins have constitutive tyrosine kinase activity and activate multiple signal transduction pathways. These pathways and the fusion proteins are attractive targets for tar...Continue Reading

Citations

May 1, 2007·Current Hematologic Malignancy Reports·Sonja BurgstallerNicholas C P Cross
Jan 1, 2008·Current Hematologic Malignancy Reports·Animesh Pardanani, Ayalew Tefferi
Jun 8, 2013·International Journal of Hematology·John Jeongseok YangTae Sung Park
Oct 14, 2003·The Lancet Oncology·Daniel BirnbaumMax Chaffanet
Apr 26, 2007·Nature Reviews. Cancer·Thomas ForceRichard A Van Etten
Oct 16, 2007·Oncogene·R A Van Etten
Jul 15, 2005·The New England Journal of Medicine·Daniela S Krause, Richard A Van Etten
Jan 27, 2007·Current Opinion in Hematology·Ayalew Tefferi, James W Vardiman
Oct 16, 2009·Journal of Pediatric Hematology/oncology·Wenyong W ZhangDolores López-Terrada
Jun 22, 2010·Journal of Pediatric Hematology/oncology·Xiangli ChenLinxiang Liu
Nov 23, 2007·The Cancer Journal·Animesh Pardanani, Srdan Verstovsek
Jul 5, 2005·Acta Haematologica·A Tefferi
Jun 9, 2009·PloS One·Mohamed BouzaffourSophie Vriz
Jul 9, 2004·International Journal of Hematology·Ayalew Tefferi, Animesh Pardanani
Feb 28, 2014·The New England Journal of Medicine·Amir T FathiRobert P Hasserjian
Oct 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·Dimple BansalBrian J P Huntly
Dec 3, 2005·Leukemia & Lymphoma·Maria E Nelson, David P Steensma
Feb 16, 2016·Oncogene·Z ShiZ Zhou
Dec 20, 2007·Expert Review of Molecular Diagnostics·Rowena S Lewis, Alister C Ward
Sep 1, 2007·Expert Opinion on Medical Diagnostics·Brijesh Arora, Ayalew Tefferi
May 3, 2014·Nigerian Medical Journal : Journal of the Nigeria Medical Association·O John-Olabode SarahxS Akanmu Alani
Mar 17, 2010·American Journal of Clinical Pathology·Jeffery M KlcoJohn L Frater
Jul 17, 2009·American Journal of Clinical Pathology·Juergen Thiele
Jun 13, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Haiyang XieShusen Zheng
Jul 9, 2003·British Journal of Haematology·Barbara J Bain
Jul 11, 2006·British Journal of Haematology·Asim Khwaja
Aug 2, 2006·European Journal of Haematology·Katsuya YamamotoToshimitsu Matsui
May 10, 2006·British Journal of Haematology·Ayalew TefferiAnimesh Pardanani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.